ATI RN
ATI Pharmacology
1. A client with prostate cancer is receiving leuprolide. Which of the following findings should the nurse monitor?
- A. Increased testosterone levels
- B. Increased libido
- C. Gynecomastia
- D. Hypoglycemia
Correct answer: C
Rationale: The nurse should monitor the client for gynecomastia when receiving leuprolide as it can cause decreased testosterone levels, leading to the development of gynecomastia. Choices A, B, and D are incorrect because leuprolide actually decreases testosterone levels, which would not result in increased testosterone levels or libido. Leuprolide is not associated with hypoglycemia, so monitoring for this is unnecessary in a client receiving this medication.
2. A client's serum Calcium is 8.8 mg/dL. Which of the following medications should the nurse anticipate administering to this client?
- A. Calcitonin-salmon
- B. Calcium carbonate
- C. Zoledronic acid
- D. Ibandronate
Correct answer: B
Rationale: The client's serum calcium level is below the expected reference range. In this case, the appropriate medication to anticipate administering is Calcium carbonate, an oral form of calcium used to increase serum calcium levels to the expected reference range.
3. A client is receiving Enoxaparin for the prevention of deep vein thrombosis. Which of the following actions should the nurse take?
- A. Massage the injection site after administration.
- B. Administer the medication intramuscularly.
- C. Administer the medication into the subcutaneous tissue.
- D. Administer the medication into the deltoid muscle.
Correct answer: C
Rationale: Enoxaparin, a medication used for preventing deep vein thrombosis, should be administered into the subcutaneous tissue, typically in the abdomen. Administering the medication intramuscularly (Choice B) or into the deltoid muscle (Choice D) is incorrect because Enoxaparin is specifically formulated for subcutaneous administration. Massaging the injection site after administration (Choice A) is contraindicated as it may lead to tissue damage and affect the absorption of the medication. Therefore, the correct action is to administer the medication into the subcutaneous tissue as directed.
4. What is an expected outcome for Lithium use in patients with bipolar disorder?
- A. Reduced risk of myocardial infarction
- B. Reduced risk of GI ulcers
- C. Decrease in respiratory distress
- D. Decreased incidence of acute manic episodes
Correct answer: D
Rationale: The correct answer is D: Decreased incidence of acute manic episodes. Lithium is commonly used to treat bipolar disorder by helping to stabilize mood and reduce the intensity and frequency of manic episodes. This leads to better overall management of the disorder. Choices A, B, and C are incorrect because lithium is not known to reduce the risk of myocardial infarction, GI ulcers, or respiratory distress in patients with bipolar disorder.
5. A client with Diabetes is experiencing Nausea due to Gastroparesis. The healthcare provider should anticipate a prescription for which of the following medications?
- A. Lubiprostone
- B. Metoclopramide
- C. Bisacodyl
- D. Loperamide
Correct answer: B
Rationale: Metoclopramide, a dopamine antagonist, is indicated for treating nausea and increasing gastric motility. In the context of diabetic gastroparesis, it can alleviate bloating and nausea by enhancing gastric emptying. Lubiprostone (Choice A) is a chloride channel activator used for chronic idiopathic constipation and irritable bowel syndrome with constipation. Bisacodyl (Choice C) is a stimulant laxative primarily used for constipation. Loperamide (Choice D) is an anti-diarrheal agent and would not be appropriate for treating nausea and gastroparesis.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access